@article{cbc8f26dfcec4a87b17a7510d6282f92,
title = "First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis",
abstract = "Background Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAF(V600)-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAF(V600)-mutant melanoma patients. Methods We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAF(V600)-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. Results Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7-24.3) and 85.4% (95% CI: 58.1-73.6) vs. 41.7% (95% CI: 34.2-51.0). Conclusions Our data suggest that in the matched BRAF(V600)-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.",
keywords = "dabrafenib, ipilimumab, metastatic melanoma, nivolumab, pembrolizumab, phase-3, pooled analysis, vemurafenib, DABRAFENIB, PHASE-3, METASTATIC MELANOMA, PEMBROLIZUMAB, POOLED ANALYSIS, NIVOLUMAB, IPILIMUMAB, VEMURAFENIB",
author = "{van Breeschoten}, J. and M.W.J.M. Wouters and D.L. Hilarius and J.B. Haanen and C.U. Blank and M.J.B. Aarts and {van den Berkmortel}, F.W.P.J. and {de Groot}, J.W.B. and G.A.P. Hospers and E. Kapiteijn and D. Piersma and {van Rijn}, R.S. and K.P.M. Suijkerbuijk and W.A.M. Blokx and {ten Tije}, B.J.J. and {van der Veldt}, A.A.M. and A. Vreugdenhil and M.J. Boers-Sonderen and {van den Eertwegh}, A.J.M.",
year = "2021",
month = mar,
day = "30",
doi = "10.1038/s41416-020-01229-1",
language = "English",
volume = "124",
pages = "1222--1230",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",
}